Skip to main content

Dante Labs, Cambridge Cancer Genomics, Nonacus Collaborate to Build Tumor Profiling Service

NEW YORK ─ Dante Labs, Cambridge Cancer Genomics (CCG.ai), and Nonacus said on Monday that they have inked a collaboration agreement to build a high-throughput cancer sequencing and interpretation service for tumor profiling that enables improved patient management, treatment, and monitoring.

The firms said that the service will combine Dante Labs’ experience and capacity in delivering a sequencing service for solid tumor and cell-free circulating tumor DNA from liquid biopsies with Nonacus’ targeted pan-cancer NGS libraries and CCG.ai’s AI-based software platform, OncOS.

Financial and other terms of the agreement were not disclosed.

As a result of the agreement, oncologists and clinical researchers will be able to send samples to L'Aquila, Italy-based Dante Labs, which will use library preparation kits from Nonacus and software from Cambridge, UK-based CCG.ai to create a sample-to-report service. The report will recommend the correct treatments for actionable mutations and generate matches with possible clinical trials when the mutations are novel or not actionable, the firms said.

"Long turnaround time and lack of clinically oriented analysis are the main obstacles to fully deliver the potential of cancer genomics to patients," Chris Sale, CEO of Birmingham, UK-based Nonacus, said in a statement. "This partnership will provide the flexibility and accuracy that oncology professionals need to integrate cancer genomics into the care of their patients."

Such a high-throughput precision oncology service will help provide the scale required to address a backlog of cancer patient samples due to the COVID-19 pandemic, the firms said.